Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New breast cancer study findings reported from M. Aapro and co-authors
May 15th, 2008
" The Breast Cancer-Anemia and the Value of Erythropoietin ( BRAVE) study evaluated whether epoetin beta would improve survival in patients with metastatic breast cancer ( MBC). Patients and Methods BRAVE was an open-label, randomized, multicenter study in patients with MBC treated with anthracycline- and/or taxane-based chemotherapy," researchers in Switzerland report. "Patients ( hemoglobin [ Hb] < 12.9 g/dL) were randomly assigned ( 1: 1) to epoetin beta 30,000 U subcutaneously once weekly or control for 24 weeks. The primary efficacy variable was overall survival. Secondary efficacy outcomes included progression-free survival, transfusion- and severe anemia-free...
Source: Women's Health Weekly (2008-05-15)
|
